ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. will pay Eisai $750 million plus milestone payments of up to $4 billion to jointly develop Eisai’s lenvatinib mesylate, a small-molecule tyrosine kinase inhibitor already approved to treat certain cancers. The two firms will develop the drug, sold as Lenvima, as a monotherapy and in combination with Merck’s Keytruda anti-PD-1 cancer therapy. “There is strong scientific evidence supporting synergistic effects of Keytruda when used in combination with Lenvima,” says Roger M. Perlmutter, president of Merck Research Laboratories.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X